← Acorda Therapeutics (ACOR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Acorda Therapeutics (ACOR)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
14
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CVT-301 | Phase 3 | Idiopathic Parkinson's Disease |
| 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | Phase 2 | Multiple Sclerosis |
| dalfampridine-ER 7.5mg | Phase 3 | Post-Ischemic Stroke |
| Tizanidine | Phase 2 | Spasticity |
| Diazepam | Phase 2 | Epilepsy |
| Fampridine-SR | Phase 3 | Multiple Sclerosis |
| Dalfampridine-ER 5mg | Phase 3 | Multiple Sclerosis |
| CVT-301 Low Dose | Phase 3 | Idiopathic Parkinson's Disease |
| Fampridine-SR b.i.d. (Twice Daily) | Phase 3 | Multiple Sclerosis |
| Dalfampridine | Phase 2 | Spinal Cord Injury |
| Nepicastat | Phase 2 | Posttraumatic Stress Disorder |
| Dalfampridine Pill | Phase 3 | Multiple Sclerosis |
| SYN120 | Phase 2 | Parkinson's Disease Dementia (PDD) |
| Sinemet (carbidopa/levodopa) | Phase 2 | Idiopathic Parkinson's Disease |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACOR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.